− / − (NSG) xenograft mice are currently the most frequently used model to study human leukemia in vivo, the absence of a human niche severely hampers faithful recapitulation of the disease. We used NSG mice in which ceramic scaffolds seeded with human mesenchymal stromal cells were implanted to generate a human bone marrow (huBM-sc)-like niche. We observed that, in contrast to the murine bone marrow (mBM) niche, the expression of BCR-ABL or MLL-AF9 was sufficient to induce both primary acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). Stemness was preserved within the human niches as demonstrated by serial transplantation assays. Efficient engraftment of AML MLL-AF9 and blast-crisis chronic myeloid leukemia patient cells was also observed, whereby the immature blast-like phenotype was maintained in the huBM-sc niche but to a much lesser extent in mBM niches. We compared transcriptomes of leukemias derived from mBM niches versus leukemias from huBM-like scaffold-based niches, which revealed striking differences in the expression of genes associated with hypoxia, mitochondria and metabolism. Finally, we utilized the huBM-sc MLL-AF9 B-ALL model to evaluate the efficacy of the I-BET151 inhibitor in vivo. In conclusion, we have established human niche models in which the myeloid and lymphoid features of BCR-ABL + and MLL-AF9 + leukemias can be studied in detail.
INTRODUCTION
Establishing xenograft models is essential to study the molecular mechanisms involved in human leukemias aimed at improving treatment options. Currently, NOD-SCID IL2Rγ − / − (NSG) xenograft models are considered as the gold standard for evaluating the engraftment of human hematological malignancies. However, despite being the most immune compromised mouse strain available allowing a more efficient and faster disease development compared with other NOD/SCID-related strains, [1] [2] [3] NSG mice are also suboptimal as 30-40% of primary acute myeloid leukemia (AML) samples failed to engraft. 4 Obviously, a human bone marrow (huBM) environment is lacking in these animals, and such a humanized niche might be essential to provide the optimum concentration of endogenous cytokines, chemokines and adhesion factors to allow efficient engraftment and maintenance of different leukemia clones. Indeed, engraftment of normal human CD34 + cells in NSG mice is lymphoid biased. Using retroviral/ lentiviral systems to model human leukemias, we frequently observe that while in vitro both myeloid and lymphoid transformation can be achieved upon expression of oncogenes such as MLL-AF9 or BCR-ABL/BMI1, in vivo transformation is strongly biased toward acute lymphocytic leukemia (ALL). 5, 6 In patients, the BCR-ABL p210 oncoprotein can give rise to both myeloid and lymphoid leukemias, and the same is true for MLL-AF9 in pediatric leukemia patients. Together, these observations suggest that a specific human microenvironment might be necessary for engraftment and maintenance of self-renewal of myeloid leukemic stem cells (LSCs). As certain myeloid growth factors are often species specific, the mouse niche does not suffice to provide the appropriate environment for human LSCs.
To develop in vivo models that more faithfully recapitulate human disease driven by the BCR-ABL p210 translocation and by MLL-AF9, we made use of a humanized niche NSG xenograft model in which ceramic scaffolds coated with human mesenchymal stromal cells (MSCs) were implanted in NSG mice where they developed into structures mimicking a huBM microenvironment. 7, 8 Next we studied the engraftment and initiation of CML by cord blood (CB) CD34 + cells transduced with BCR-ABL with or without BMI1 (where indicated) or with MLL-AF9, as well as engraftment of primary CML and AML patient cells. Our data indicate that serially transplantable ALL and primary AML could be established in the humanized scaffold xenograft model. Differences between transcriptome profiles of BCR-ABL cells harvested from murine and human niches were analyzed, and thus we identified niche-specific BCR-ABL signatures. Ultimately, we also took advantage of the huBM-sc MLL-AF9 B-ALL model to evaluate the efficacy of I-BET151 inhibitor in vivo.
MATERIALS AND METHODS

Establishment of the humanized scaffold niche xenograft model
The ectopic bone model was established as described previously. 7, 8 Briefly, four hybrid scaffolds consisting of three 2-3-mm biphasic calcium phosphate particles loaded with human MSCs were implanted subcutaneously into 8-week-old female NOD.Cγ-Prkdcscid Il2rγtm1Wjl/SzJ (NSG) mice. Neonatal CB samples were obtained after informed consent from 1 healthy full-term pregnancies from the obstetrics departments of the University Medical Center in Groningen and Martini Hospital Groningen. CB CD34 + cells were isolated as described previously. 6, 9 Five hundred thousand non-sorted cells were directly injected into the scaffolds or intravenously (i.v.) as indicated during primary as well as secondary transplantations. CD45 engraftment was analyzed by timely bleeding procedures.
Retroviral and lentiviral transductions
The murine stem cell virus (MSCV)-BMI1-internal ribosomal entry site (IRES2)-enhanced green fluorescent protein and MSCV-BCR-ABL-IRES2-truncated nerve growth factor receptor (tNGFR) retroviral vectors were cloned into MiGR1 and MiNR1 as previously described. 6 MLL-AF9 vectors were described previously. 5, 10 Transductions of CB CD34 + cells were performed as described previously. 6, 9 Long-term culture-initiating cell (LTC-IC) assay
For the LTC-IC assays, newly transduced cells were sorted on MS5 stromal cells in limiting dilutions from 10 to 500 cells per well in 96-well plates as described previously. 9 After 5 weeks of culture, the wells containing cobblestone areas were scored, after which the medium from the wells was aspirated and replaced with methylcellulosecontaining cytokines. After an additional 2 weeks of culture, wells were scored as positive or negative to yield the LTC-IC frequency. Stem cell frequencies were calculated using the L-Calc software (Stem Cell Technologies, Vancouver, BC, Canada).
Further materials and methods are provided as Supplementary Information.
RESULTS
Murine versus human extrinsic cues dictate transformation potential in BCR-ABL/BMI1-and MLL-AF9-induced leukemia in humanized xenograft models We have evaluated human BCR-ABL-, BCR-ABL/BMI1-and MLL-AF9-driven leukemogenesis in the murine BM niche using classical NSG xenotransplantation models and compared that to leukemogenesis in the presence of a humanized BM microenvironment. In line with what we observed previously, 6 only cells expressing both BCR-ABL and BMI1 were able to generate CD34 + /CD19 + B-ALL in the mouse BM environment when injected i.v. into sublethally irradiated NSG mice (Figures 1a, c and d and Supplementary Table S1 ). Infiltration of double-positive ALL cells was seen in the spleen and liver ( Supplementary Figures S1a and b) , and no myeloid or erythroid cells expressing CD33, CD11b, CD15 or GPA were observed in leukemic mice.
Next we injected non-sorted CB CD34 + cells transduced with BCR-ABL and BMI1 directly into a humanized model that is based on subcutaneous implantation of human BM-like scaffolds (huBM-sc), as described previously. 7, 8 In 11-21 weeks, 11 out of the 13 mice developed palpable tumors at the site of injection and data for all these 11 mice are summarized in Figure 1a , Supplementary  Table S1 and Supplementary Figure S1c . In contrast to i.v. injected mice that all developed CD19 + B-ALL, in transcutaneous injected huBM-sc mice both CD19 + B-ALL phenotypes and CD19 − AML phenotypes were observed (Figures 1c and d, Supplementary  Table S1 ). When transduced cells were injected into empty scaffolds or scaffolds coated with MSCs that were irradiated with 30 Gy prior to implantation, leukemia development was never Table S1 ).
When freshly transduced CB MLL-AF9 cells were transplanted i.v. into NSG mice, a CD19 + lymphoid leukemia could be generated within 11-25 weeks, and again myeloid engraftment was difficult to achieve. In only about 10% of the cases, mixedlineage leukemias were observed in which both CD19 + B-ALL and CD33 + /CD19 − myeloid clones were only observed, in line with previous observations. 5, 11 Upon direct injection of CB MLL-AF9 into huBM-sc mice, all animals developed a fatal leukemia with a latency of 16-32 weeks. Although leukemia development was still biased toward CD19 + B-ALL, more mixed leukemias with both B-ALL and AML clones were observed within the humanized niche, and in one case AML without B-ALL clones was observed (Figures 1c and d, Supplementary Table S1 ). Overall, leukemia development was slightly slower in the huBM-sc model compared with the muBM i.v. model (although the difference did not reach significance, Mantel-Cox test P = 0.0678), possibly related to the observation that myeloid leukemias developed less fast compared with lymphoid B-ALLs. Table S1 ). Apparently, in a humanized microenvironment, co-expression of exogenous BMI1 was not required to induce BCR-ABL-positive leukemia.
Furthermore, the huBM-sc allowed for the development of a variety of phenotypes ranging from B-ALL with aberrant expression of myeloid markers to more erythroid-and myeloid-biased leukemias, regardless of whether these were BCR-ABL singlepositive or BCR-ABL and BMI1 double-positive clones. Table S1 ).
In the huBM-sc mouse m1, the developing tumors were more compact and red (huBM scaffold 3) or green (huBM scaffolds 1 and 4), indicative of erythroid development and myeloperoxidase expression, respectively. These were CD19 neg but did express intermediate-to-high levels of GPA and CD33, with the highest expression of GPA in huBM scaffold 3 ( Figure 2f Clearly, huBM-sc were sufficiently vascularized to allow migration of tumor cells from injected scaffolds to non-injected scaffolds, as well as to mouse compartments. Ligation-mediated PCRs were performed to study clonality ( Supplementary Figures S3b-d) . We observed that multiple co-existing clones and integration sites could be identified that were different in independent experiments. Furthermore, in mice in which one scaffold was the most dominant growing one (for example, Sc2 in mouse 5, Supplementary Figure S3b ) not only similar integrations sites were found in the human scaffold and the murine BM (for example, the red integration site) but also that slight changes in clonality were observed as well (for example, the yellow integrations site in BM and Sc2). In other cases where multiple scaffolds generated leukemias, different unique clones could engraft in individually injected scaffolds (Sc1 versus Sc3, indicated by different colors), whereby one clone that was seen in the dominant clone in BM (red clone) was also seen in the scaffolds. And finally, in a secondary transplantation experiment most but not all primary clones were seen in secondary leukemias grown in the scaffolds or BM (Supplementary Figure S3d , Sc2 in mouse 1 versus second Sc1-3 and BM, red integration site), although some integration sites were only seen in one scaffold (Sc3, green integration site), and additional clones appeared upon second transplantation as well (Sc2-3, yellow integration site), which were most likely quiescent in the primary transplant.
In 3/8 huBM-sc mice (m1-m3), exclusively CD19 + B-ALL was observed in the scaffolds, with phenotypes resembling those we previously observed in i.v. injected NSG mice without human niches (Horton et al., 5 Rizo et al. 6 and Figures 3a-d, Supplementary  Table S1 ). Within these mice, infiltration to mouse organs was observed as well, displaying phenotypes similar to those in the humanized scaffolds. Some mice displayed a somewhat more mature leukemic B-ALL phenotype with the presence of CD19 + / CD20 + clones (data not shown). In 4 out of the 8 huBM-sc mice (m4-m7), both B-ALL as well as myeloid CD19 − /CD33 + clones were detected (Figure 3e, Supplementary Table S1, Supplementary Figure S3 ), and in one mouse (m8) one scaffold was completely lymphoid while another was completely myeloid. Within this myeloid clone, some co-expression of myeloid markers such as CD11b, CD15 and CD14 with CD33 was also detected, resembling the phenotype we observe in in vitro myeloid cultures as well as in patients, and the lymphoid and myeloid phenotypes were confirmed by MGG staining (Figures 3f and g ).
In total, and in contrast with murine niches, out of the 24 engrafted scaffolds we observed co-existing myeloid and lymphoid clones in 9 cases (37.5%) and a complete myeloid clone in 1 case (4.1%), although this difference did not reach statistical significance (P = 0.0804). Taken together, these data suggest that the ectopic human BM microenvironment provides a more permissive microenvironment to drive LSCs toward myeloid differentiation.
Self-renewal is maintained within human niches as shown by serial transplantation but remains lymphoid biased In order to evaluate the self-renewal potential of BCR-ABL singlepositive leukemic clones, we performed secondary transplantations. Cells harvested from huBM scaffold 3 of mouse m5 were Establishing BCR-ABL + and MLL-AF9 + human niche xenograft models P Sontakke et al transplanted into three sub-lethally irradiated NSG mice carrying huBM scaffolds, such that three scaffolds were inoculated with 0.16 × 10 6 cells per scaffold, while one scaffold was left uninjected (Supplementary Figure S4a) . Large tumors were observed in all three secondary transplanted mice, and within 6 weeks, mice presented with overt leukemia (Figures 1a and d, Supplementary  Figure S4b ). All injected huBM scaffolds of all three secondary transplanted mice contained BCR-ABL single-positive cells. FACS analyses indicated that different clones had engrafted into individual scaffolds. Some scaffolds contained CD19-, CD38-and CD33-positive cells comparable to their phenotype in primary mice, although expression of CD15 was lost ( Supplementary  Figures S4c-e) . huBM scaffold 2 from mouse m5.1 displayed multiple clones that varied in tNGFR expression, suggesting different levels of BCR-ABL expression in these clones. Clones with intermediate levels of BCR-ABL expression were positive for GPA while clones with the highest expression of BCR-ABL did not express GPA but in contrast expressed high levels of CD19 (Supplementary Figure S4f and data not shown) . Infiltration of BCR-ABL single-positive cells was also observed to some extent in the BM, spleen and liver, although chimerism levels were very low (Supplementary Table S1 ). Establishing BCR-ABL + and MLL-AF9 + human niche xenograft models P Sontakke et al
To obtain further insight into the clonality of these different engrafting populations, we performed ligation-mediated PCR on cells harvested from primary as well as secondary huBM scaffolds. As shown in Supplementary Figure S4g , multiple bands were observed suggesting the coexistence of multiple clones. The clone indicated by the red asterisk was detected in both the primary and all secondary transplanted animals. Furthermore, multiple different other integration sites were observed in secondary leukemic mice, indicative for oligoclonal disease. As a number of these clones were not detected in the primary mouse, these data suggest the presence of quiescent clones in the primary leukemic cell population that were activated upon serial transplantation.
In order to assess the self renewal potential of CB MLL-AF9 leukemic cells generated in huBM-sc of primary recipients, we also performed secondary transplantation. CD19 + /CD15
+ lymphoid leukemic cells harvested from mouse m1 huBM-Sc2 were transplanted into humanized NSG mice. Tumor formation was observed in all the injected scaffolds and FACS analyses displayed the same phenotype observed in the primary recipient, although expression of CD15 + was lost (Supplementary Figure S4h) . Infiltration of CB MLL-AF9-positive cells was also observed in the BM, spleen and liver, albeit the chimerism levels were lower in comparison to primary recipients (Supplementary Table S1 ). Furthermore, we performed a secondary transplantation using cells from m6 huBM-Sc2 that contained two distinct clones of CD33 + (78.3%) and CD19 + (~3%). Because of the small number of cells available, only a single secondary huBM-sc could be injected with 1x10 5 unsorted cells. Tumor formation was observed in the Figure S4i) , a feature we have observed more frequently. These results indicate that despite the presence of a human niche microenvironment, MLL-AF9-induced transformation of neonatal CB CD34 + cells remain biased toward B-ALL.
Molecular characterization of cells derived from the murine niche versus the human niche Illumina microarray analysis was performed to study transcriptome differences between murine niche-and human niche-derived BCR-ABL-positive cells. BCR-ABL cells harvested from scaffolds from primary mice (first huBM-sc), BCR-ABL cells harvested from scaffolds from secondary transplanted mice (second huBM-sc) as well as primary BCR-ABL/BMI1 cells harvested from murine BM and spleen (first mBM/Spleen) were compared. Five hundred and seventy-seven probesets were significantly upregulated in the huBM-sc-derived leukemic cells compared with the mBM/ Spleen-derived cells, while 458 probesets were downregulated (corrected P-value o 0.01 with Benjamini-Hochberg multiple testing correction, more than threefold differentially expressed, Supplementary Table S2 ). These data indicate that significant differences existed in transcriptome signatures between leukemias that developed in the mBM versus huBM scaffold niches. The top differentially expressed genes are shown in the supervised cluster analysis in Figure 4a , indicating that the first A supervised hierarchical clustering analyses of differentially expressed genes is shown (differentially expressed genes were determined by using a corrected P-valueo 0.01 with BenjaminiHochberg multiple testing correction, and more than threefold difference in expression levels, Supplementary Table S1). Primary and secondary huBM-sc samples clustered together, away from all three primary i.v. injected samples. BMI1, CDKN1C/p57 and MYC were some of the interesting candidate genes upregulated in huBM-sc first and second scaffold derived samples. Establishing BCR-ABL + and MLL-AF9 + human niche xenograft models P Sontakke et al huBM-sc sample clustered tightly together with the eight second huBM-sc samples, while all three first mBM/Spleen samples clustered together, away from all huBM-sc samples. Gene Ontology analyses indicated that the huBM-sc-overexpressed genes were significantly (false-discovery rate o 1) enriched for processes, such as apoptosis and mitochondrion. Genes upregulated in mBM-derived leukemias were significantly (false-discovery rate o1) enriched for Gene Ontology terms methylation and histone core-related genes (Figure 4b ). Gene Set Enrichment Analysis indicated that huBM scaffold-derived leukemias were enriched for MYC targets and hypoxia signatures, suggesting that BCR-ABL-positive cells derived from the humanized scaffold display differences in MYC dependency and hypoxic state as compared with mBM-derived leukemias (Figure 4c) . A number of selected Gene Ontology terms for genes upregulated in huBM scaffold-derived leukemias are shown in Figure 5d and Supplementary Figure S5 . Interestingly, p57 and MYC were some of the significantly overexpressed secreted proteins in huBM scaffold-derived leukemias. Another interesting observation was that endogenous BMI1 was overexpressed in BCR-ABL-positive cells derived from humanized scaffolds, possibly explaining why exogenously overexpressed BMI1 is not required as is the case for leukemias that develop in the murine BM niche. Illumina data were validated by independent Q-PCR analyses (Figure 4e ). Figure S6a) . Cells in the mBM niche displayed a more differentiated phenotype in terms of a higher proportion of cells expressing the markers CD11b, CD14 and CD15 while a lower proportion of cells expressed CD34 (Figure 5c , Supplementary  Figures S6a-c) . In contrast, leukemic cells derived from the huBM scaffold more closely resembled the original patient and in particular CD34 percentages were quite comparable (Figure 5c , Supplementary Figures S6a-c) . These FACS analyses were confirmed by immunohistochemistry (Supplementary Figure S6b) .
The self-renewing potential of cells harvested from the murine BM niche and those retrieved from the human niche in the huBM scaffolds was functionally studied in the LTC-IC assays. CD34 + and CD34
− cells were sorted and plated in limiting dilution and were scored after 5 weeks. No cobblestone area-forming cells were detected at week 5 in CD34 + or CD34 − isolated from murine BM-harvested cells (Supplementary Figure S6d) , and only differentiated macrophages could be observed (data not shown). In contrast, cobblestone area-forming cells could readily be detected in cultures initiated with CD34 + cells isolated from the huBM scaffold-harvested cells, with an LTC-IC frequency of 1 in 323 ± 115 (Supplementary Figure S6d) . Thus these results suggest that selfrenewal of LT BC-CML LSCs was maintained in the context of a humanized BM niche. Maintenance of self-renewal was also demonstrated in vivo by serial transplantation assays (Antonelli, Groen and Schuringa, to be submitted).
Finally, Q-PCR analyses was performed on BC-CML samples harvested from the mouse BM and human scaffold niches, and similar as observed in our BCR-ABL retroviral overexpression models, a significantly increased level of endogenous BMI1 was observed in cells derived from human scaffolds (Supplementary Figure S6e) .
Finally, we also injected primary MLL-AF9 AML patient material into huBM-sc of a NSG mouse. Two scaffolds were injected with 1x10 6 cells each. Although we did not detect any CD45 + chimerism in the blood during the course of the experiment, we killed the mouse 20 weeks after transplantation upon palpation of tumor growth on one of the scaffolds (Figure 5e ). Cells retrieved from the huBM-Sc3 displayed a myeloid phenotype with the expression of CD33, CD11b and CD15 (Figure 5f ), which was further confirmed by MGG staining of cytospins (Figure 5g) . No human cells could be detected in mouse organs such as the spleen, liver and or BM by FACS analyses (Figure 5f ), and the spleen size was not enlarged (weight: 0.12 g).
I.sc. in vivo treatment with IBET151
We next evaluated whether the huBM-sc model could also be used for drug testing. In our in vitro CB MLL-AF9 myeloid and lymphoid MS5 co-culture system, we observed that, upon inhibition of BRD3/4 binding to acetylated histones with the small-molecule I-BET151, 12, 13 proliferation was severely impaired (data not shown). Here we assessed the therapeutic potential of I-BET151 in vivo in our huBM-sc B-ALL CB MLL-AF9 xenograft model. In all, 5 × 10 5 cells harvested from a primary B-ALL MLL-AF9 generated in huBM-sc mice were injected into three huBM scaffolds of secondary recipients, while the fourth scaffold was left uninjected. Four weeks after injection of the cells, we performed daily i.sc. injections of the inhibitor for a total of 23 days. One control group (n = 5) was injected with a solution of phosphate-buffered saline and dimethyl sulfoxide 1%, one group (n = 3) with I-BET151 500 μM and another group (n = 5) with I-BET151 5 mM. Tumor volume size of each scaffold was measured during the experiment every 3 days, allowing us to monitor the progression of the disease in time. All mice were killed at the same time at day 54 after injection. Mice treated with 5 mM I-BET151 displayed a significant reduction in tumor volume (approximately twofold, P o0.0001). Accordingly, also the cell number of the cells harvested from the tumors was significantly different (for the 500-μM group P = 0.04, for the 5-mM group P = 0.01) (Figures 6a-d) . No significant differences were found in spleen weight or blood and BM chimerism. Together, these data indicate that I-BET151 treatment significantly delays lymphoid leukemia progression in vivo but is not sufficient for a complete eradication of the leukemic cells, at least not in this experimental setting.
DISCUSSION
Despite many advantages of various xenotransplantation mouse models for human leukemias that have been developed till date, faithful recapitulation of myeloid phenotypes and efficient maintenance of long-term self-renewal of LSCs has remained challenging. One of the fundamental drawbacks of currently available mouse models to study human leukemias is the absence of a human microenvironment that would potentially provide species-specific cytokines, growth factors and adhesion molecules that are essential for self-renewal and myelopoiesis. Here we used our previously developed humanized mouse model that provides a human BM-like scaffold-based (huBM-sc) microenvironment 7, 8 in which human myeloid and lymphoid leukemias can be studied in detail.
Various retroviral/lentiviral models have been established to model human myeloid and lymphoid leukemias, and while in vitro BCR-ABL or MLL-AF9 oncogenes (either alone or in combination with other hits) could induce transformation along myeloid or lymphoid lineages, in vivo transformation was always heavily lymphoid biased and in vivo myeloid transformation has been much more difficult to achieve in NOD-SCID-based xenograft Establishing BCR-ABL + and MLL-AF9 + human niche xenograft models P Sontakke et al models, including the NSG mice. 5, 6, 11, 14 Furthermore, a significant number of primary AML samples does not engraft in the NSG mouse model 4 , again pinpointing to the notion that a niche that allows self-renewal of myeloid (malignant) clones is not provided for in the NSG mouse. Over the past years, xenograft leukemia models have already been significantly improved, and advantages and disadvantages of various humanized mouse models have recently been nicely reviewed.
3,15 NOD/SCID-3/GM/SF mice engineered to produce human IL3, GM-CSF and SF 16, 17 and NOD-SCID IL2Rγ
− / − (NSG) mice expressing human interleukin 3 (IL3), granulocyte-macrophages colony-stimulating factor (GM-CSF) and steel factor (SF) (NS-SGM3) 18 have been generated, which enhanced engraftability of primary human AML samples, as well as others, [19] [20] [21] [22] [23] including MISTRG mice expressing M-CSF, IL3, GM-CSF, thrombopoietin (TPO) and SIRPα. 19 Even myelodysplastic syndrome patient samples or myelodysplastic syndrome-derived cell lines were reported to engraft making use of human cytokine mice. 24, 25 These models are clearly useful tools, although other human niche-specific factors might still be missing.
We made use of a humanized mouse xenograft model that harbors a human BM-like niche in which we could recapitulate both the myelomonocytic and B-ALL phenotypes that are observed in MLL-AF9 pediatric patients. Compared with the murine environment of NOD-SCID/NSG mice, a higher percentage of myeloid clones could be generated in the huBMsc model. This observation reinforces the notion that the lineage fate of MLL-AF9 LSCs is dictated primarily by microenvironmental cues and cell of origin rather than an instructive role of the fusion partner gene. Although we could easily serially transplant huBM-sc derived B-ALL clones, second engraftment of myeloid clones was more difficult to achieve. Possibly, the level of myeloid growth factors such as IL3, 14 an important and species-specific growth factor for myeloid leukemias driven by MLL-AF9, are still too low in our huBM-sc model. Ongoing experiments include further improvement of the huBM-sc model using MSCs that we have genetically engineered to express cytokines, such as IL3 and TPO. On the other hand, Wei et al.
14 reported that upon injection of CB CD34 + cells transduced with MLL-AF9 into NS-SGM3 mice only AML but not B-ALL developed, suggesting that these mice are now strongly biased toward myelopoiesis. Besides lentiviral models for MLL-AF9, we also showed that primary AML MLL-AF9 derived from an adult patient could engraft efficiently in the huBM-sc, and it will be interesting to compare the human cytokine mice with our humanized niche scaffold model side-by-side in future experiments.
We also find that primary CD34 + CML patient cells can efficiently engraft in this xenograft model, whereby stemness is much better preserved in the human environment as compared with the mouse environment. Furthermore, we describe that this humanized niche model also allows for BCR-ABL-driven myeloid and lymphoid disease, in contrast to the NOD-SCID/NSG mouse in which exclusively CD19 + B-ALL was observed upon transplantation of transduced CB CD34 + cells (current study and Nicolini et al. 16 ). Our previous studies in NSG mice showed that BCR-ABL as single hit was never sufficient to induce leukemia in the context of a murine niche, 6 in line with data published by others. 26 Only when additional hits were provided, such as co-expression of BMI1, a serially transplantable CD19 + B-ALL could be induced. 6 Possibly, BMI1 was required to bypass (oncogene-induced) senescence, and also in mouse models BMI1 was shown to reprogram BCR-ABL + lymphoid progenitors into B-ALL-initiating cells. 27 In the huBM-sc xenograft model that we present here, transformation was achieved with both BCR-ABL-only expressing cells as well as with cells that expressed both BCR-ABL and BMI1. Apparently, exogenous BMI1 is not an absolute requirement to allow transformation of human CB CD34 + cells transduced with only BCR-ABL.
Finally, striking differences were observed between transcriptomes of leukemic cells derived from murine BM niches versus leukemic cells derived from the huBM scaffold niches, including in genes associated with hypoxia signaling, mitochondria and metabolism. Within the top differentially expressed genes, there was enrichment for cell cycle inhibitors, such as CDKN1C/p57, and hypoxic signature-related genes in the humanized microenvironment, genes that have been shown to contribute to stemness of hematopoietic stem cells/LSCs. [28] [29] [30] [31] [32] Also, we find that endogenous Establishing BCR-ABL + and MLL-AF9 + human niche xenograft models P Sontakke et al BMI1 was strongly upregulated in the human BM niche. Apparently, the human BM niche can provide for factors that induce BMI1 expression, possibly through activation of SALL4 or the Sonic Hedgehog pathway, which both have been shown to be able to induce BMI1 expression. 33, 34 In conclusion, we describe here a huBM-sc xenograft model in which the myeloid and lymphoid features of MLL-AF9 and BCR-ABL + leukemias can be studied in detail, both using lentiviral/retroviral model systems as well as patient samples, in which the efficacy of novel drugs can be evaluated.
